Intuitive Surgical (ISRG) saw a pre-market gain of 1.55% on February 18, 2026, after reporting strong Q1 2026 earnings, beating EPS and revenue estimates, driven by its da Vinci systems and AI-enabled diagnostics. Despite a rich valuation with a P/E of 62.69, analysts remain constructive with an average target of $617.23, and Meyka AI projects a 22.50% upside to $604.32, highlighting growth opportunities in digital tools but also risks from high valuation and insider selling. The company’s next earnings report is scheduled for April 21, 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
ISRG Intuitive Surgical (NASDAQ) pre-market +1.55% 18 Feb 2026: analysts’ targets
Intuitive Surgical (ISRG) saw a pre-market gain of 1.55% on February 18, 2026, after reporting strong Q1 2026 earnings, beating EPS and revenue estimates, driven by its da Vinci systems and AI-enabled diagnostics. Despite a rich valuation with a P/E of 62.69, analysts remain constructive with an average target of $617.23, and Meyka AI projects a 22.50% upside to $604.32, highlighting growth opportunities in digital tools but also risks from high valuation and insider selling. The company’s next earnings report is scheduled for April 21, 2026.